JP2017515797A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017515797A5 JP2017515797A5 JP2016560726A JP2016560726A JP2017515797A5 JP 2017515797 A5 JP2017515797 A5 JP 2017515797A5 JP 2016560726 A JP2016560726 A JP 2016560726A JP 2016560726 A JP2016560726 A JP 2016560726A JP 2017515797 A5 JP2017515797 A5 JP 2017515797A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- oxo
- membered
- pyrrolidin
- cyclopropylmethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- 239000003112 inhibitor Substances 0.000 claims 20
- 229910052731 fluorine Inorganic materials 0.000 claims 17
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 14
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 13
- 229910052801 chlorine Inorganic materials 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 229910052794 bromium Inorganic materials 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 8
- 239000000556 agonist Substances 0.000 claims 7
- -1 cyclopropylmethoxy Chemical group 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 125000001963 4 membered heterocyclic group Chemical group 0.000 claims 6
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 6
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 6
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 230000009977 dual effect Effects 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 4
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 4
- 102100040918 Pro-glucagon Human genes 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 3
- DGENZVKCTGIDRZ-UHFFFAOYSA-N 3-[4-[(3-phenoxyphenyl)methylamino]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1NCC1=CC=CC(OC=2C=CC=CC=2)=C1 DGENZVKCTGIDRZ-UHFFFAOYSA-N 0.000 claims 3
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims 3
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims 3
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 3
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 3
- 229940044601 receptor agonist Drugs 0.000 claims 3
- 239000000018 receptor agonist Substances 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 claims 2
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 claims 2
- 108010064733 Angiotensins Proteins 0.000 claims 2
- 102000015427 Angiotensins Human genes 0.000 claims 2
- AASMFGPLTAEVSZ-MZVUKIKXSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(CC(C2=CC1)CC(=O)O)=O)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(CC(C2=CC1)CC(=O)O)=O)=O AASMFGPLTAEVSZ-MZVUKIKXSA-N 0.000 claims 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 2
- 108030001679 Endothelin-converting enzyme 1 Proteins 0.000 claims 2
- 102000048186 Endothelin-converting enzyme 1 Human genes 0.000 claims 2
- 229940125827 GPR40 agonist Drugs 0.000 claims 2
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims 2
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims 2
- 102000016267 Leptin Human genes 0.000 claims 2
- 108010092277 Leptin Proteins 0.000 claims 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 229940126033 PPAR agonist Drugs 0.000 claims 2
- 102000001253 Protein Kinase Human genes 0.000 claims 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 2
- 230000003276 anti-hypertensive effect Effects 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 2
- 239000002792 enkephalinase inhibitor Substances 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 229940039781 leptin Drugs 0.000 claims 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 claims 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 108060006633 protein kinase Proteins 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims 1
- 229940124681 11 beta HSD inhibitor Drugs 0.000 claims 1
- IGRCWJPBLWGNPX-UHFFFAOYSA-N 3-(2-chlorophenyl)-n-(4-chlorophenyl)-n,5-dimethyl-1,2-oxazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N(C)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl IGRCWJPBLWGNPX-UHFFFAOYSA-N 0.000 claims 1
- FODHWOBAQBTTFS-UHFFFAOYSA-N 3-[4-[2-(2-methylphenyl)ethynyl]phenyl]propanoic acid Chemical compound CC1=CC=CC=C1C#CC1=CC=C(CCC(O)=O)C=C1 FODHWOBAQBTTFS-UHFFFAOYSA-N 0.000 claims 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 claims 1
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 claims 1
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 claims 1
- USKXYXPBOMGLLD-BDPMCISCSA-N 5-[(3R)-3-[6-(cyclopropylmethoxy)pyridin-3-yl]oxy-2-oxopyrrolidin-1-yl]-7-fluoro-N,N-dimethyl-3-oxo-1,2-dihydroindene-1-carboxamide Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(CC(C2=C(C1)F)C(=O)N(C)C)=O)=O USKXYXPBOMGLLD-BDPMCISCSA-N 0.000 claims 1
- MPLLLQUZNJSVTK-UHFFFAOYSA-N 5-[3-[4-[2-(4-fluorophenyl)ethoxy]phenyl]propyl]furan-2-carboxylic acid Chemical compound O1C(C(=O)O)=CC=C1CCCC(C=C1)=CC=C1OCCC1=CC=C(F)C=C1 MPLLLQUZNJSVTK-UHFFFAOYSA-N 0.000 claims 1
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims 1
- 229940121969 Aminopeptidase A inhibitor Drugs 0.000 claims 1
- 102000008873 Angiotensin II receptor Human genes 0.000 claims 1
- 108050000824 Angiotensin II receptor Proteins 0.000 claims 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 1
- 101100460776 Arabidopsis thaliana NPY2 gene Proteins 0.000 claims 1
- 101100460782 Arabidopsis thaliana NPY4 gene Proteins 0.000 claims 1
- 101100460788 Arabidopsis thaliana NPY5 gene Proteins 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- 102100034159 Beta-3 adrenergic receptor Human genes 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- BAVBIEINCBQCIS-XJQHNOHDSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CC(C(C2=C1)=O)(CC(=O)OC)CC(=O)O)F)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CC(C(C2=C1)=O)(CC(=O)OC)CC(=O)O)F)=O BAVBIEINCBQCIS-XJQHNOHDSA-N 0.000 claims 1
- CVOBRTBACYTQDG-MZVUKIKXSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CC(C(C2=C1)=O)CC(=O)NC)F)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CC(C(C2=C1)=O)CC(=O)NC)F)=O CVOBRTBACYTQDG-MZVUKIKXSA-N 0.000 claims 1
- ZOMGPSDHJAEBMP-VXNXSFHZSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CC(C(C2=C1)=O)CC(=O)NCCO)F)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CC(C(C2=C1)=O)CC(=O)NCCO)F)=O ZOMGPSDHJAEBMP-VXNXSFHZSA-N 0.000 claims 1
- PTCLXIBMVGZCLW-YBMSBYLISA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CC(C(C2=C1)=O)CC(=O)O)F)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CC(C(C2=C1)=O)CC(=O)O)F)=O PTCLXIBMVGZCLW-YBMSBYLISA-N 0.000 claims 1
- HDMJFZVQKWIGHK-MZVUKIKXSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CC(C(C2=C1)=O)CC(=O)OC)F)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CC(C(C2=C1)=O)CC(=O)OC)F)=O HDMJFZVQKWIGHK-MZVUKIKXSA-N 0.000 claims 1
- VHKCUZZKFAOONF-GFOWMXPYSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CC(C(C2=C1)=O)C(=O)OC)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CC(C(C2=C1)=O)C(=O)OC)=O VHKCUZZKFAOONF-GFOWMXPYSA-N 0.000 claims 1
- XCPFCMJLLCURTH-FBLFFUNLSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CC(C(C2=C1)=O)CC(=O)OC)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CC(C(C2=C1)=O)CC(=O)OC)=O XCPFCMJLLCURTH-FBLFFUNLSA-N 0.000 claims 1
- KHMVPLWHVHKWBX-MZVUKIKXSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(C(CC2=C(C1)F)CCO)=O)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(C(CC2=C(C1)F)CCO)=O)=O KHMVPLWHVHKWBX-MZVUKIKXSA-N 0.000 claims 1
- YFFNGNRATOREJB-VCUSLETLSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(C(CC2=C(C=1)F)CC(=O)N1CCOCC1)=O)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(C(CC2=C(C=1)F)CC(=O)N1CCOCC1)=O)=O YFFNGNRATOREJB-VCUSLETLSA-N 0.000 claims 1
- VQQIQCMLBFIJBI-VXNXSFHZSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(CC(C2=C(C1)F)CC(=O)N(C)C)=O)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(CC(C2=C(C1)F)CC(=O)N(C)C)=O)=O VQQIQCMLBFIJBI-VXNXSFHZSA-N 0.000 claims 1
- PPBVJDCNPZEOLC-YBMSBYLISA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(CC(C2=C(C1)F)CC(=O)O)=O)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(CC(C2=C(C1)F)CC(=O)O)=O)=O PPBVJDCNPZEOLC-YBMSBYLISA-N 0.000 claims 1
- KNCCRZYEOLWZSA-YBMSBYLISA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(CC(C2=C(C=1)F)CO)=O)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(CC(C2=C(C=1)F)CO)=O)=O KNCCRZYEOLWZSA-YBMSBYLISA-N 0.000 claims 1
- HOBNXWPWQJXRMG-IRCUZVAFSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(CC(C2=CC1)CC(=O)N(C)C)=O)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(CC(C2=CC1)CC(=O)N(C)C)=O)=O HOBNXWPWQJXRMG-IRCUZVAFSA-N 0.000 claims 1
- PPAPEDJRDXEEMY-VXNXSFHZSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(CC(C2=CC1)CC(=O)NC)=O)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(CC(C2=CC1)CC(=O)NC)=O)=O PPAPEDJRDXEEMY-VXNXSFHZSA-N 0.000 claims 1
- JMNSEEZJYUMJBG-VXNXSFHZSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(CC(C2=CC1)CC(=O)OC)=O)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(CC(C2=CC1)CC(=O)OC)=O)=O JMNSEEZJYUMJBG-VXNXSFHZSA-N 0.000 claims 1
- XLZSUXDBSGHDKV-VXNXSFHZSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(CC(C2=CC1)CCO)=O)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(CC(C2=CC1)CCO)=O)=O XLZSUXDBSGHDKV-VXNXSFHZSA-N 0.000 claims 1
- SUVSQEXUGZOACJ-MZVUKIKXSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(CC(C2=CC=1)CO)=O)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(CC(C2=CC=1)CO)=O)=O SUVSQEXUGZOACJ-MZVUKIKXSA-N 0.000 claims 1
- AASMFGPLTAEVSZ-YCRPNKLZSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(C[C@H](C2=CC1)CC(=O)O)=O)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(C[C@H](C2=CC1)CC(=O)O)=O)=O AASMFGPLTAEVSZ-YCRPNKLZSA-N 0.000 claims 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 claims 1
- 229940123158 Cannabinoid CB1 receptor antagonist Drugs 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims 1
- 229940123239 Cholesterol synthesis inhibitor Drugs 0.000 claims 1
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 claims 1
- 102100036869 Diacylglycerol O-acyltransferase 1 Human genes 0.000 claims 1
- 108050004099 Diacylglycerol O-acyltransferase 1 Proteins 0.000 claims 1
- 229940097420 Diuretic Drugs 0.000 claims 1
- DVJAMEIQRSHVKC-BDAKNGLRSA-N Dutogliptin Chemical compound OB(O)[C@@H]1CCCN1C(=O)CN[C@H]1CNCC1 DVJAMEIQRSHVKC-BDAKNGLRSA-N 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 102400000686 Endothelin-1 Human genes 0.000 claims 1
- 101800004490 Endothelin-1 Proteins 0.000 claims 1
- LCDDAGSJHKEABN-MLGOLLRUSA-N Evogliptin Chemical compound C1CNC(=O)[C@@H](COC(C)(C)C)N1C(=O)C[C@H](N)CC1=CC(F)=C(F)C=C1F LCDDAGSJHKEABN-MLGOLLRUSA-N 0.000 claims 1
- NNRMUDCEMYUOLQ-OODIQHKMSA-N FC1=CC=C(OC2=CC=C(C=N2)O[C@H]2C(N(CC2)C=2C=C3C(CC(C3=CC2)CCO)=O)=O)C=C1 Chemical compound FC1=CC=C(OC2=CC=C(C=N2)O[C@H]2C(N(CC2)C=2C=C3C(CC(C3=CC2)CCO)=O)=O)C=C1 NNRMUDCEMYUOLQ-OODIQHKMSA-N 0.000 claims 1
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 claims 1
- 101710182387 Fibroblast growth factor receptor 4 Proteins 0.000 claims 1
- 102100040134 Free fatty acid receptor 4 Human genes 0.000 claims 1
- 102000027487 Fructose-Bisphosphatase Human genes 0.000 claims 1
- 108010017464 Fructose-Bisphosphatase Proteins 0.000 claims 1
- 102100025353 G-protein coupled bile acid receptor 1 Human genes 0.000 claims 1
- 229940100607 GPR119 agonist Drugs 0.000 claims 1
- 229940123483 GPR142 agonist Drugs 0.000 claims 1
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 claims 1
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 claims 1
- ZWPRRQZNBDYKLH-VIFPVBQESA-N Gemigliptin Chemical compound C([C@@H](N)CC(=O)N1CC2=C(C(=NC(=N2)C(F)(F)F)C(F)(F)F)CC1)N1CC(F)(F)CCC1=O ZWPRRQZNBDYKLH-VIFPVBQESA-N 0.000 claims 1
- 206010071602 Genetic polymorphism Diseases 0.000 claims 1
- 101800001586 Ghrelin Proteins 0.000 claims 1
- 102400000442 Ghrelin-28 Human genes 0.000 claims 1
- 108010063919 Glucagon Receptors Proteins 0.000 claims 1
- 102100040890 Glucagon receptor Human genes 0.000 claims 1
- 229940123232 Glucagon receptor agonist Drugs 0.000 claims 1
- 229940122904 Glucagon receptor antagonist Drugs 0.000 claims 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 claims 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 claims 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 claims 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 claims 1
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 claims 1
- 229920002527 Glycogen Polymers 0.000 claims 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 claims 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 claims 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 claims 1
- 101000890672 Homo sapiens Free fatty acid receptor 4 Proteins 0.000 claims 1
- 101000857733 Homo sapiens G-protein coupled bile acid receptor 1 Proteins 0.000 claims 1
- 101000996752 Homo sapiens Glucose-dependent insulinotropic receptor Proteins 0.000 claims 1
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims 1
- 102100030643 Hydroxycarboxylic acid receptor 2 Human genes 0.000 claims 1
- 101710125793 Hydroxycarboxylic acid receptor 2 Proteins 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 229940125922 IBAT inhibitor Drugs 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 108010001831 LDL receptors Proteins 0.000 claims 1
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 claims 1
- 229940127470 Lipase Inhibitors Drugs 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims 1
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 claims 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
- 101150111774 NPY5R gene Proteins 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 102000018886 Pancreatic Polypeptide Human genes 0.000 claims 1
- 101710176384 Peptide 1 Proteins 0.000 claims 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 1
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims 1
- GSINGUMRKGRYJP-VZWAGXQNSA-N Remogliflozin Chemical compound C1=CC(OC(C)C)=CC=C1CC1=C(C)N(C(C)C)N=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 GSINGUMRKGRYJP-VZWAGXQNSA-N 0.000 claims 1
- 102000013272 Renalase Human genes 0.000 claims 1
- 108010090629 Renalase Proteins 0.000 claims 1
- 108090000783 Renin Proteins 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims 1
- 108091006300 SLC2A4 Proteins 0.000 claims 1
- 229940123451 Somatostatin receptor 3 agonist Drugs 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 claims 1
- 229940123464 Thiazolidinedione Drugs 0.000 claims 1
- 229940123876 Thyroid hormone receptor beta agonist Drugs 0.000 claims 1
- ZXOCGDDVNPDRIW-NHFZGCSJSA-N Tofogliflozin Chemical compound O.C1=CC(CC)=CC=C1CC1=CC=C(CO[C@@]23[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C2=C1 ZXOCGDDVNPDRIW-NHFZGCSJSA-N 0.000 claims 1
- 102000008316 Type 4 Melanocortin Receptor Human genes 0.000 claims 1
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 claims 1
- 101710204865 Tyrosine-protein phosphatase 1 Proteins 0.000 claims 1
- 102400000752 Xenin Human genes 0.000 claims 1
- 229960002632 acarbose Drugs 0.000 claims 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 claims 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 1
- 229960002478 aldosterone Drugs 0.000 claims 1
- 239000002170 aldosterone antagonist Substances 0.000 claims 1
- 229940083712 aldosterone antagonist Drugs 0.000 claims 1
- 229960001667 alogliptin Drugs 0.000 claims 1
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 claims 1
- 239000002160 alpha blocker Substances 0.000 claims 1
- 108010028144 alpha-Glucosidases Proteins 0.000 claims 1
- 229950009977 anagliptin Drugs 0.000 claims 1
- LDXYBEHACFJIEL-HNNXBMFYSA-N anagliptin Chemical compound C=1N2N=C(C)C=C2N=CC=1C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N LDXYBEHACFJIEL-HNNXBMFYSA-N 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 claims 1
- 150000004283 biguanides Chemical class 0.000 claims 1
- 239000003613 bile acid Substances 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 229960001713 canagliflozin Drugs 0.000 claims 1
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 claims 1
- 239000003555 cannabinoid 1 receptor antagonist Substances 0.000 claims 1
- 229960005110 cerivastatin Drugs 0.000 claims 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims 1
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 claims 1
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 239000002604 chemokine receptor CCR2 antagonist Substances 0.000 claims 1
- 229960003834 dapagliflozin Drugs 0.000 claims 1
- 238000006356 dehydrogenation reaction Methods 0.000 claims 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 229940125542 dual agonist Drugs 0.000 claims 1
- 229940125436 dual inhibitor Drugs 0.000 claims 1
- 229950003693 dutogliptin Drugs 0.000 claims 1
- 229960003345 empagliflozin Drugs 0.000 claims 1
- OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 229950011259 evogliptin Drugs 0.000 claims 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims 1
- 229960000815 ezetimibe Drugs 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 claims 1
- 229960002458 gemigliptin Drugs 0.000 claims 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 claims 1
- 229940124828 glucokinase activator Drugs 0.000 claims 1
- 230000036252 glycation Effects 0.000 claims 1
- 229940096919 glycogen Drugs 0.000 claims 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 229940125425 inverse agonist Drugs 0.000 claims 1
- 229950000991 ipragliflozin Drugs 0.000 claims 1
- AHFWIQIYAXSLBA-RQXATKFSSA-N ipragliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(F)C(CC=2SC3=CC=CC=C3C=2)=C1 AHFWIQIYAXSLBA-RQXATKFSSA-N 0.000 claims 1
- 229960002397 linagliptin Drugs 0.000 claims 1
- 230000037356 lipid metabolism Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229950004994 meglitinide Drugs 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 229960003105 metformin Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229950009116 mevastatin Drugs 0.000 claims 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims 1
- 239000002395 mineralocorticoid Substances 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 229940012843 omega-3 fatty acid Drugs 0.000 claims 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 1
- 239000004031 partial agonist Substances 0.000 claims 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 claims 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 claims 1
- 239000003358 phospholipase A2 inhibitor Substances 0.000 claims 1
- 229960005095 pioglitazone Drugs 0.000 claims 1
- 229960002797 pitavastatin Drugs 0.000 claims 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229960002965 pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- 102000016670 prohibitin Human genes 0.000 claims 1
- 108010028138 prohibitin Proteins 0.000 claims 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical group O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 229940126844 remogliflozin Drugs 0.000 claims 1
- 229950011516 remogliflozin etabonate Drugs 0.000 claims 1
- UAOCLDQAQNNEAX-ABMICEGHSA-N remogliflozin etabonate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)OCC)O[C@H]1OC1=NN(C(C)C)C(C)=C1CC1=CC=C(OC(C)C)C=C1 UAOCLDQAQNNEAX-ABMICEGHSA-N 0.000 claims 1
- 239000002461 renin inhibitor Substances 0.000 claims 1
- 229940086526 renin-inhibitors Drugs 0.000 claims 1
- 229960004586 rosiglitazone Drugs 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- 229960004937 saxagliptin Drugs 0.000 claims 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 claims 1
- 108010033693 saxagliptin Proteins 0.000 claims 1
- 229940126842 sergliflozin Drugs 0.000 claims 1
- HFLCZNNDZKKXCS-OUUBHVDSSA-N sergliflozin Chemical compound C1=CC(OC)=CC=C1CC1=CC=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HFLCZNNDZKKXCS-OUUBHVDSSA-N 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 229960004034 sitagliptin Drugs 0.000 claims 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 229950000034 teneligliptin Drugs 0.000 claims 1
- WGRQANOPCQRCME-PMACEKPBSA-N teneligliptin Chemical compound O=C([C@H]1NC[C@H](C1)N1CCN(CC1)C1=CC(=NN1C=1C=CC=CC=1)C)N1CCSC1 WGRQANOPCQRCME-PMACEKPBSA-N 0.000 claims 1
- 150000001467 thiazolidinediones Chemical class 0.000 claims 1
- 229950006667 tofogliflozin Drugs 0.000 claims 1
- 239000003174 triple reuptake inhibitor Substances 0.000 claims 1
- 229960001254 vildagliptin Drugs 0.000 claims 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 claims 1
- IDHVLSACPFUBDY-QCDLPZBNSA-N xenin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CN=CN1 IDHVLSACPFUBDY-QCDLPZBNSA-N 0.000 claims 1
- 108010006643 xenin 25 Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14305491.4 | 2014-04-04 | ||
| EP14305491 | 2014-04-04 | ||
| PCT/EP2015/057413 WO2015150563A1 (en) | 2014-04-04 | 2015-04-02 | Substituted indanone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017515797A JP2017515797A (ja) | 2017-06-15 |
| JP2017515797A5 true JP2017515797A5 (enExample) | 2018-05-17 |
Family
ID=50513188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016560726A Abandoned JP2017515797A (ja) | 2014-04-04 | 2015-04-02 | 糖尿病、肥満、脂質異常症および関連障害の治療のためのｇｐｒ１１９モジュレーターとしての置換インダノン化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9896434B2 (enExample) |
| EP (1) | EP3126346B1 (enExample) |
| JP (1) | JP2017515797A (enExample) |
| KR (1) | KR20160132887A (enExample) |
| CN (1) | CN106132949A (enExample) |
| AU (1) | AU2015239020A1 (enExample) |
| CA (1) | CA2942121A1 (enExample) |
| IL (1) | IL248118A0 (enExample) |
| MX (1) | MX2016013029A (enExample) |
| RU (1) | RU2016143092A (enExample) |
| SG (1) | SG11201606619UA (enExample) |
| WO (1) | WO2015150563A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3126346B1 (en) | 2014-04-04 | 2018-07-11 | Sanofi | Substituted indanone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders |
| US10392366B2 (en) | 2017-02-21 | 2019-08-27 | Sanofi | Azetidine compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders |
| KR101943382B1 (ko) | 2017-09-19 | 2019-01-29 | 오토텔릭바이오 주식회사 | Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물 |
| ES3035734T3 (en) * | 2017-11-30 | 2025-09-08 | Idorsia Pharmaceuticals Ltd | Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases |
| KR102131359B1 (ko) * | 2018-09-07 | 2020-07-07 | 오토텔릭바이오 주식회사 | 안정성이 향상된 의약 조성물 |
| EP3873877A1 (en) * | 2018-10-31 | 2021-09-08 | Basf Se | Process for producing hydroxymethyl-alcohols |
| WO2020197926A1 (en) * | 2019-03-22 | 2020-10-01 | Kallyope, Inc. | Gpcr combination therapies |
| EP3976053A4 (en) * | 2019-05-31 | 2022-11-23 | Avolynt | COMPOSITIONS AND METHODS OF TREATING A METABOLIC DISEASE |
| PH12022552277A1 (en) | 2020-02-28 | 2024-03-04 | Kallyope Inc | Gpr40 agonists |
| KR102289381B1 (ko) * | 2020-03-17 | 2021-08-17 | 주식회사 대웅테라퓨틱스 | 당뇨치료제 및 고지혈증 치료제를 포함하는 약학적 조성물 |
| CA3178994A1 (en) | 2020-05-19 | 2021-11-25 | Iyassu Sebhat | Ampk activators |
| JP2023531726A (ja) | 2020-06-26 | 2023-07-25 | キャリーオペ，インク． | Ａｍｐｋアクチベーター |
| KR20250113341A (ko) * | 2024-01-18 | 2025-07-25 | 주식회사 티에치팜 | 나트륨 포도당 운반체-2 저해제 및 안지오텐신 ⅱ 수용체 차단제를 함유하는 비만 예방 또는 치료용 약학적 조성물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005521651A (ja) | 2001-12-31 | 2005-07-21 | アクテリオン ファマシューティカルズ リミテッド | ピロリドンカルボキサミド類 |
| BRPI0410561A (pt) * | 2003-06-18 | 2006-06-20 | Pfizer Prod Inc | lactamas de piperazinileteroarilóxi-n-arill e de piperazinilarilóxi |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| BR112012029395A2 (pt) * | 2010-05-17 | 2016-07-26 | Array Biopharma Inc | lactamas piperdinil-substituídas como moduladores de gpr119 |
| AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
| JP2013537234A (ja) | 2010-09-17 | 2013-09-30 | アレイ バイオファーマ、インコーポレイテッド | Ｇｐｒ１１９モジュレーターとしてのピペリジニル置換ラクタム |
| CA2853784A1 (en) | 2011-11-11 | 2013-05-16 | Glaxosmithkline Llc | Treatment of blood lipid abnormalities and other conditions |
| AR092924A1 (es) * | 2012-10-09 | 2015-05-06 | Sanofi Sa | Derivados de pirrolidinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados |
| EP3126346B1 (en) | 2014-04-04 | 2018-07-11 | Sanofi | Substituted indanone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders |
-
2015
- 2015-04-02 EP EP15713527.8A patent/EP3126346B1/en not_active Not-in-force
- 2015-04-02 SG SG11201606619UA patent/SG11201606619UA/en unknown
- 2015-04-02 WO PCT/EP2015/057413 patent/WO2015150563A1/en not_active Ceased
- 2015-04-02 RU RU2016143092A patent/RU2016143092A/ru not_active Application Discontinuation
- 2015-04-02 CA CA2942121A patent/CA2942121A1/en not_active Abandoned
- 2015-04-02 CN CN201580017436.4A patent/CN106132949A/zh active Pending
- 2015-04-02 JP JP2016560726A patent/JP2017515797A/ja not_active Abandoned
- 2015-04-02 MX MX2016013029A patent/MX2016013029A/es unknown
- 2015-04-02 AU AU2015239020A patent/AU2015239020A1/en not_active Abandoned
- 2015-04-02 KR KR1020167027277A patent/KR20160132887A/ko not_active Withdrawn
- 2015-04-02 US US15/301,603 patent/US9896434B2/en not_active Expired - Fee Related
-
2016
- 2016-09-29 IL IL248118A patent/IL248118A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017515797A5 (enExample) | ||
| JP2017509678A5 (enExample) | ||
| JP2017509679A5 (enExample) | ||
| RU2016143092A (ru) | Замещенные соединения инданона в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных с ними нарушений | |
| US10428076B2 (en) | Soluble guanylate cyclase stimulators | |
| US12448384B2 (en) | Diacylglyceride O-acyltransferase 2 inhibitors | |
| KR20110067096A (ko) | 당뇨병 및 관련 상태를 치료하기 위한 병용 요법 | |
| US20150274712A1 (en) | sGC STIMULATORS | |
| JP2013523819A5 (enExample) | ||
| JP2017509678A (ja) | 糖尿病、肥満、脂質異常症および関連障害の治療のためのｇｐｒ１１９モジュレーターとしてのイソインドリノン化合物 | |
| EP3585775A1 (en) | Azetidine compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | |
| JP2013537242A5 (enExample) | ||
| KR20150038706A (ko) | 디펩티딜 펩티다아제 억제제의 주1회 투여 | |
| RU2009111378A (ru) | Терапевтические композиции, содержащие специфический антагонист рецептора эндотелина и ингибиторов pde5 | |
| MXPA05009789A (es) | Combinacion de un antagonista del receptor de aldosterona y un agente antidiabetico. | |
| AU2017360939A1 (en) | Indazole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 | |
| WO2010107610A1 (en) | Method for treatment of diabetes and related conditions with combination therapy and compositions containing such compounds | |
| EP3541376A1 (en) | Indole derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2 | |
| CN101822837A (zh) | 包含艾力沙坦酯盐的药物组合物 | |
| US11976061B2 (en) | Preparation of benzimidazolone derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | |
| CN101822836A (zh) | 包含艾力沙坦酯的药物组合物 | |
| JP2023541714A (ja) | 新規なジアシルグリセリドｏ－アシルトランスフェラーゼ２阻害剤としてのオキシインドール誘導体の製造 | |
| CN101822667A (zh) | 包含咪唑-5-羧酸类衍生物的药物组合物 | |
| US20240254114A1 (en) | Preparation of fused azole derivatives as novel diacylglyceride 0-acyltransferase 2 inhibitors | |
| CN101466707A (zh) | 用于对抗依赖于肾素活性的疾病的吡咯烷衍生物 |